子宫内膜癌复发的当代表现与诊断:何时、何处及如何?
该回顾性研究分析了2014至2020年间确诊的子宫内膜癌患者,评估复发模式、表现及诊断方式。复发患者中60%有症状,疼痛最常见,有症状者接受复发治疗的可能性较低(76.7% vs 91.3%,p=0.005),但总生存无差异。超过三分之一的复发由肿瘤团队以外的提供者诊断。
要点
- 复发患者中60%(120/201)有症状,疼痛最常见(23.4%,47/201),出血<14%(28/201)。
- 有症状者接受复发治疗的可能性较低(76.7% vs 91.3%,p=0.005),但总生存无差异。
- 无症状盆腔检查诊断复发占13.4%(27/201),更多见于初诊早期、子宫内膜样组织学且未接受辅助治疗者。
核心结论
- 大多数复发性子宫内膜癌患者有症状,疼痛是常见主诉。
- 有症状表现者接受复发治疗的可能性较低,但未导致总生存差异。
- 鉴于子宫内膜癌死亡率上升,需要进一步工作制定多学科监测策略以实现有意义的复发治疗。
研究设计与样本
- 回顾性审查2014至2020年间诊断为子宫内膜癌的女性,评估疾病复发,病历回顾聚焦复发时的表现。
- 使用χ2、Fisher精确检验、t检验和Wilcoxon检验评估关系,Kaplan-Meier乘积极限估计生存,多元逻辑回归评估协变量影响。
主要发现
- 201例(11.7%)患者发现子宫内膜癌复发。
- 60%(120/201)患者有症状,疼痛最常见(23.4%,47/201),出血<14%(28/201)。
- 有症状者接受复发治疗的可能性较低(76.7% vs 91.3%,p=0.005)。
- 无症状盆腔检查诊断复发占13.4%(27/201),更多见于初诊早期疾病(66.7% vs 34.5%,p=0.001)、子宫内膜样组织学(66.7% vs 36.8%,p=0.003)且未接受辅助治疗(48.2% vs 17.9%,p=0.001)的患者。
- 超过三分之一的诊断由肿瘤护理团队以外的提供者做出。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine patients with confirmed endometrial cancer recurrence; evaluate patterns, presentation, and mode of diagnosis. STUDY DESIGN: A retrospective review of women with endometrial cancer diagnosis between 2014 and 2020. Disease recurrences were evaluated. Medical records were reviewed focusing on presentation at time of recurrence. Relationships were assessed using χ2, Fisher's exact test, t-test, and Wilcoxon test. The Kaplan-Meier product limit was used to estimate survival. Multiple logistic regression analysis was used to assess the impact of covariates. RESULTS: Endometrial cancer recurrence was identified in 201 (11.7%) patients. Sixty percent (120/201) of patients presented with symptoms. Pain was the most common presenting symptom (23.4%, 47/201) and bleeding was reported in <14% (28/201). Patients with symptomatic presentation were less likely to be able to receive treatment for their recurrent disease (76.7% vs 91.3%, p = 0.005). Asymptomatic pelvic exam diagnosed recurrence in 13.4% (27/201) and was more common in patients initially diagnosed with early-stage disease (66.7% vs 34.5% p = 0.001) of endometrioid histology (66.7% vs 36.8%, p = 0.003) without prior adjuvant therapy (48.2% vs 17.9%, p = 0.001). More than1/3 of diagnoses were made by providers outside of the oncologic care team. CONCLUSION: The majority of women with recurrent endometrial cancer were symptomatic and pain is a common complaint associated with disease recurrence. Patients with symptomatic presentation of disease recurrence were less likely to receive treatment for recurrent disease but this did not result in an overall survival (OS) difference. Given the rising mortality rate of endometrial cancer further work is needed to develop multidisciplinary surveillance strategies that will enable meaningful treatment of disease recurrence.
引用
- Riedinger CJ, Patterson JM, Backes FJ, et al. The contemporary presentation and diagnosis of endometrial cancer recurrence: When, where, and how? Gynecol Oncol. 2022. PMID: 36154763. doi:10.1016/j.ygyno.2022.09.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。